Annexon, Inc. (ANNX)
Develops medicines targeting immune system diseases like nerve inflammation and nerve degeneration.
$4.97-0.03%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+102.9%
The outlook
Annexon trades near $5, currently below both its 50- and 200-day moving averages after a modest decline today. Analysts lean bullish with a buy consensus, and the average price target implies 173% upside from here. The stock sits mid-range in its 52-week band, with a mix of technical weakness and analyst optimism.
What’s behind the score
Analyst consensusBuy — 1.6 avg of 9 analysts
Price trendBelow its 50- & 200-day averages
52-week range57% of the way from its 52-week low to high
Price targetAvg target +173% vs current price
Analyst price target
~12-month · 9 analysts$13.56average target+172.7% vs now
Now $4.97
Low $3.00High $27.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$814.3M
52-wk high
$7.18
52-wk low
$2.03
50-day avg
$5.36
200-day avg
$5.09
Trailing P/E
—